Clinical Trial

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Study acronym: CLINCH-2
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-15
Trial Details
NCT Number NCT07327229
Lead Sponsor Antengene Biologics Limited
Collaborators: Merck Sharp & Dohme LLC
Conditions Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 132 participants
Start Date 2026-02-27
Primary Completion 2027-09-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-29